Arrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.06) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). Arrowhead Pharmaceuticals had a negative return on equity of 90.77% and a negative net margin of 163.32%. The company had revenue of $3.55 million for the quarter, compared to analyst estimates of $35.60 million. During the same period last year, the firm posted ($0.39) EPS. The business’s quarterly revenue was down 94.3% on a year-over-year basis. On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Stock Down 0.6 %

Shares of Arrowhead Pharmaceuticals stock opened at $25.00 on Wednesday. Arrowhead Pharmaceuticals has a 52 week low of $20.67 and a 52 week high of $41.36. The business’s fifty day simple moving average is $27.10 and its 200-day simple moving average is $28.74. The firm has a market cap of $3.10 billion, a PE ratio of -8.99 and a beta of 0.78.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now directly owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Hongbo Lu acquired 1,000 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was acquired at an average price of $27.49 per share, with a total value of $27,490.00. Following the completion of the transaction, the director now owns 31,680 shares of the company’s stock, valued at $870,883.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Victoria Vakiener sold 1,799 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the transaction, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The disclosure for this sale can be found here. 4.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ARWR shares. Citigroup increased their price objective on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a report on Wednesday, February 7th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, February 8th. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $50.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $50.80.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.